Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BWVI: What %%% is his Buy Call up now?
I never heard of this company. Buy more! 🤣
Your buy call is now DOWN 54.8 percent in just six (6) trading days.
So your typical performance.
VWAP= $ 0.013307 Total$Vol= $ 5,467
When will Capn Keith find the brain chips on the Pulaski??
everyone knows that their main office is a virtual office, right?
Yeah check my stock picks, 1 is up 68% today. 🤣
Why? Why? Why?
Capn KEITH and BWVI take a deep dive and gett DaBenz, Badd mushrooms from DaWrecked
In the news today Compass pathways trading at $11 and reporting Target price of $33 to $120. Go BWV $$$
Exactly big cat, in the news musks neurolink just completed their first implant and touting 50 billion dollar market
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173216590
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173225685
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172915343
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172642646
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172956044
Dude, this scam with its rent-a-mailbox office is BROKE. It hasn't even been be to sell the paltry $50,000 offering and is loaded with FLOORLESS CONvertiblle debt that matures in a few munffs.
Hmmmm it will be exciting to see what steps are being taken by our newly appointed neurosurgical CEO Dr. Jha and his fellow neurosurgeon Dr. Bailes.
"The Company believes that the steps now being taken will enable the Company to maximize future opportunities and compete more effectively with significantly less debt on the balance sheet and more capital for growth."
https://www.accesswire.com/825669/psycheceutical-bioscience-strategically-pivots-into-the-brain-computer-interface-bci-space
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
MIAMI, FL / ACCESSWIRE / January 17, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of neurological treatments, appointed Neilank K. Jha, MD, Executive Chairman and CEO on November 1, 2023 to initiate an immediate turnaround to avert restructuring for operational, financial and regulatory reasons.
https://www.accesswire.com/825669/psycheceutical-bioscience-strategically-pivots-into-the-brain-computer-interface-bci-space
We have two well connected neurosurgeons leading the way here for Neuraseed/Psycheceutical. Certainly a huge connection here with the Nico Corporation.
12/12/23 Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
https://finance.yahoo.com/news/dr-neilank-jha-appointed-executive-140000521.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACKH1iEj3iRSMnGszxv7S6uBOHQSxox2acRNuIZZt83Sg0OM_vBYNMCT1hFH3d0e1IUe5qebJXcZu-l360MRc9VP_5f4-XLnOouHCryUGKVaXG8Y34XDQRsG2IOZueYJ0rNWhP-yUW44nLwHtAfH8SejDdk9niVTGRpz5ikuFrmi
Interesting informational podcast further reinforcing the connection between Dr. Bailes and the Nico Corporation. Additionally, a social media post supplementing the aforementioned connection.
Podcast: Neural Implant Podcast
Social Media: Linkedin post, Nico Corporation/Dr. Julian Bailes
Where's our VWAP? I need to stay informed here!
Study Shows First-Ever Successful Deep-Brain Implant of Computer Chip in Living Animal
A first study demonstrating successful deep-brain placement of a brain computer interface microchip into a living animal with no apparent neurological effects is now published from Julian E. Bailes, MD, a recognized leader in the field of neurosurgery and co-director of the NorthShore University HealthSystem. Dr. Bailes' work has addressed the long-standing challenge of safely accessing subcortical regions of the brain for the purpose of microchip implantation without disrupting surrounding tissue.
"This study had two intentions," Dr. Bailes explained. "The first to describe the methodology for the successful implantation of an integrated circuit (IC) into the deep subcortical brain space, and secondly, to investigate how the mammalian brain would accept or reject the IC. We wanted to learn about potential damage to the neural architecture, whether infection would arise, and if the animal could survive with minimal or no functional change after subcortical placement of the IC."
First study of successful deep-brain implant of computer could lead to new treatments for many neurological disorders.
The proof-of-concept study was published in Brain-Computer Interfaces in September and used a modified and miniaturized NICO BrainPath, the world's first navigated trans-sulcal access technology widely used in Minimally Invasive Parafascicular Surgery (MIPS) for access in the removal of brain tumors and evacuation of hemorrhagic stroke.
The use of brain-computer interface (BCI) technologies is a rapidly developing area of interest in neurosurgery and medicine as a whole. BCI technologies thus far are placed at or just below the cortical surface; however, the majority of the brain's functional architecture is in the brain's interior. NICO technologies remove the barrier of deep-brain access by providing a safe pathway for delivery of a BCI into those subcortical regions, leading to possible treatments for many neurological disorders.
"It's such an exciting time in neurosurgery and the neurosciences," said Jim Pearson, president and CEO of NICO. "We are successfully leading the industry with our innovations that enable new opportunities not just for improved patient care and better outcomes, but also for merging the latest in minimally invasive technologies with the exploding area of artificial intelligence and a new generation of therapeutic and diagnostic technologies."
Pearson added that it's also an attractive emerging market for venture capitalist funding. According to a recent Wall Street Journal article, VCs are funding start-ups with medical device alternatives to medications for common but difficult to treat brain diseases. In the first half of this year, the article reports that U.S. and European neurological medical device makers garnered over $760 million in capital – the highest total among the 12 medical device markets analyzed and higher than the cardiovascular and orthopedic device markets.
NICO Corporation has led the MIS neurosurgical field for over a decade with its patented technologies that use the natural folds of the brain to reach and remove subcortical abnormalities. It is the sponsor of ENRICH, the world's first positive surgical trial for hemorrhagic stroke in which BrainPath and the NICO Myriad were used to achieve statistically significant and clinically meaningful improvements with early surgical intervention of spontaneous ICH versus medical management.
NICO advocates for and supports development of scientific evidence promoting safe and novel approaches to brain disorders and expanding clinical research efforts in pursuit of improved patient outcomes using MIPS. Its technologies have been featured in more than 180 peer-reviewed published papers with over 550 unique authors from major academic centers.
Learn about NICO technologies at NICOneuro.com; follow us on LinkedIn and Twitter, view surgical and patient videos on YouTube.
Garbage pennyturd scam. And now with FLOORLESS CONvertible funding! See below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169966893
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170533291
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169972333
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169966994
And FLOORLESS CONvertible DEBT NOTE is the "funding"! LOLOL!!!
"Convertible Note Terms
The funding was secured under a convertible note (the "Convertible Note") with Cantheon Capital ("Cantheon"). The Convertible Note provides for draws of up to $1.3 million dollars at various stages of the clinical process (for example, for clinical trial deposit and on first patient enrollment), bears interest at 10% per annum, has a term of 12 months and converts at a 20% discount to 30 day trailing OTC list price or national exchange trading price as applicable.
LOLOL!!! Pure trash.
You hearing anything from this company about ANYTHING????
Why? So they can lose more and cultivate 2024 capital losses ..
This turd is BROKEASS and has FLOORLESS CONvertibe debt notes maturing in a few months. And they couldn't even sell a measly $50000 in new issue stock!!
This turd is dead.
Some will be gack after the 30-day wash sale period. Most prob moved on for good.
Miami, FL, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Psycheceutical, Inc., a biotechnology company dedicated to the development and commercialization of psychedelic medicines, today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
“We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans,” commented Psycheceutical CEO Chad Harman. “We will immediately begin the next steps of our growth strategy as we work to bring our revolutionary psychedelic drug delivery technologies to the market, starting with initial clinical trials.”
BWVI acquired Psycheceutical, Inc. by way of a merger, resulting in Psycheceutical becoming a wholly-owned subsidiary of BWVI. Now that the acquisition has occurred, BWVI intends to cease its previous business activities and the company will focus solely on psychedelic drug development. Once regulatory approvals have been received, the company will consummate related corporate actions, including a name and symbol change.
About Psycheceutical, Inc.
Psycheceutical, Inc. is seeking to develop cutting-edge delivery technologies for safe and effective psychedelic pharmaceutical medicines. Powered by a team with more than 100 years' combined experience in development, regulatory approval processes and commercialization across the pharmaceutical industry, Psycheceutical is on a mission to bring safety and efficacy to psychedelic compounds. Learn more at Psycheceutical.com.
Jeffrey Bahnsen
407-808-5700
jeff@bahnsenlaw.com
-------
SEE THE WEBSITE: https://psycheceutical.com/
NEWS SINCE RM COMPLETE:
https://www.otcmarkets.com/stock/BWVI/news/Psycheceuticals-Chief-Visionary-Officer-Zappy-Zapolin-Speaking-at-Legacy-Investment-Summit-Alongside-Entrepreneur-Peter-?id=349584
https://www.otcmarkets.com/stock/BWVI/news/story?e&id=2143812
https://www.otcmarkets.com/stock/BWVI/news/story?e&id=2157066
CURRENTLY WAITING ON FINRA TICKER CHANGE AS OF 04-07-22.
MORE TO COME!
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |